Abstract
Although PI3-kinase mutations are uncommon in renal cell carcinoma (RCC), the PI3-kinase/Akt signaling pathway is active in most RCC. The activation of PI3-kinase would be expected to drive protein and lipid synthesis through its effects on mTORC1 and SREBP1, respectively. PI3-kinase also activates numerous transcription factors (e.g. the FOXO family, c-myc, NF-κB) that regulate cell proliferation and viability. The consequences of blocking PI3-kinase in RCC are just now beginning to be elucidated and are expected to include effects on tumor cell proliferation, metabolism, and angiogenesis. Several PI3-kinase inhibitors currently undergoing clinical testing are active site inhibitors of mTOR as well and it is likely that these agents will prove particularly useful in the treatment of RCC.
Keywords: Everolimus, mTOR, renal cell carcinoma, PI3-kinase, temsirolimus, translation.
Current Cancer Drug Targets
Title:Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma
Volume: 13 Issue: 2
Author(s): Daniel C. Cho and James W. Mier
Affiliation:
Keywords: Everolimus, mTOR, renal cell carcinoma, PI3-kinase, temsirolimus, translation.
Abstract: Although PI3-kinase mutations are uncommon in renal cell carcinoma (RCC), the PI3-kinase/Akt signaling pathway is active in most RCC. The activation of PI3-kinase would be expected to drive protein and lipid synthesis through its effects on mTORC1 and SREBP1, respectively. PI3-kinase also activates numerous transcription factors (e.g. the FOXO family, c-myc, NF-κB) that regulate cell proliferation and viability. The consequences of blocking PI3-kinase in RCC are just now beginning to be elucidated and are expected to include effects on tumor cell proliferation, metabolism, and angiogenesis. Several PI3-kinase inhibitors currently undergoing clinical testing are active site inhibitors of mTOR as well and it is likely that these agents will prove particularly useful in the treatment of RCC.
Export Options
About this article
Cite this article as:
C. Cho Daniel and W. Mier James, Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma, Current Cancer Drug Targets 2013; 13 (2) . https://dx.doi.org/10.2174/1568009611313020003
DOI https://dx.doi.org/10.2174/1568009611313020003 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ATP-Binding Cassette Transporters at the Blood-Brain Barrier in Ischaemic Stroke
Current Pharmaceutical Design Bestatin as an Experimental Tool in Mammals
Current Drug Metabolism Pharmacogenetics of Drug Transporters and Its Impact on the Pharmacotherapy
Current Topics in Medicinal Chemistry Insights into the Role of mTOR/AMPK as a Potential Target for Anticancer Therapy
Current Drug Therapy Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer
Current Cancer Drug Targets Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Pathological Reorganization of NMDA Receptors Subunits and Postsynaptic Protein PSD-95 Distribution in Alzheimer’s Disease
Current Alzheimer Research Prevalence of ABO Blood Grouping among Hemodialysis Patients in Dubai
New Emirates Medical Journal Nanotechnology and Radiopharmaceuticals: Diagnostic and Therapeutic Approaches
Current Drug Delivery Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors
Current Cancer Drug Targets The Effect of Nicotine and Tobacco on Aortic Matrix Metalloproteinases in the Production of Aortic Aneurysm
Current Vascular Pharmacology Gas1 is a Pleiotropic Regulator of Cellular Functions: from Embryonic Development to Molecular Actions in Cancer Gene Therapy
Mini-Reviews in Medicinal Chemistry Intestinal Targeting of Drugs: Rational Design Approaches and Challenges
Current Topics in Medicinal Chemistry ABC Transporters as Potential Targets for Modulation of Drug Resistance
Mini-Reviews in Medicinal Chemistry Genus Euonymus: Chemical and Pharmacological Perception
Mini-Reviews in Organic Chemistry Interferon-Alpha in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Status and Perspectives
Current Drug Targets Classical to Current Approach for Treatment of Psoriasis: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Tumor Thermal Ablation Enhancement by Micromaterials
Current Drug Delivery G-quadruplex DNA Aptamers and their Ligands: Structure, Function and Application
Current Pharmaceutical Design Viruses and Oral Cancer: Crossreactivity as a Potential Link
Anti-Cancer Agents in Medicinal Chemistry